1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Dems Come Out Swinging During Azar Senate HELP Committee Hearing

During his first Senate confirmation hearing, top Democrats attacked Trump HHS secretary nominee Alex Azar for his ties to the pharmaceutical industry and support of right-wing ideology espoused by the White House.

Alex Azar, Trump’s HHS secretary nominee, who spoke at the Senate HELP committee 11/29/17
Alex Azar testified before the Senate HELP Committee Nov. 29. • Source: Ferdous Al-Faruque

President Trump's nominee to head the US Department of Health and Human Services underwent almost three hours of tough grilling from Democrats during a Senate committee hearing. While Republican Senators touted his past executive experience at HHS and understanding of the pharmaceutical industry practices as positives, Democrats raised concerns that he would be in the pocket of Big Pharma and sabotage the Affordable Care Act.

Alex Azar, a former Eli Lilly & Co. executive and HHS official, was grilled about his policy positions and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Global Medtech Guidance Tracker: May 2025

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.

More Haste Less Pace? Challenging The ‘Early As Possible’ Principle In Medtech Innovation

 
• By Stuart Grant

The rallying cry to start as early as possible has become increasingly common in the world of medical device development. Innovation expert Dr. Stuart Grant challenges this conventional wisdom, asking: Is "sooner" truly better, or is there a smarter path to market for your medical device?

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 
• By Natasha Barrow

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.